Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout

Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.